Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731272 · ClinicalTrials.gov registry record · Phase 2
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
A Phase 2 study of Diabetes and Cystic Fibrosis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT04731272 is a Phase 2 study of Diabetes and Cystic Fibrosis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 30 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04731272, a Phase 2 study of Diabetes and Cystic Fibrosis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial for delaying and potentially preventing CFRD development. In this study, we hypothesize that weekly administration of the long-acting glucagon-like peptide-1 (GLP-1) agonist dulaglutide will improve defective early-phase insulin secretion and improve glucose tolerance during a mixed-meal tolerance test.
Conditions Studied
Interventions
- DRUG Dulaglutide 0.75Mg/0.5Ml Inj Pen
Study Locations (2)
Colorado
- Children's Hospital of Colorado - Aurora
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04731272
The ClinicalTrials.gov registry entry for NCT04731272 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Dulaglutide 0.75Mg/0.5Ml Inj Pen is the first listed.
NCT04731272 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04731272 about?
NCT04731272 is a clinical study titled "GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance". Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in...
What is the current status of trial NCT04731272?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-07-16. Estimated completion is 2027-06-30.
What conditions does trial NCT04731272 study?
This clinical trial studies the following conditions: Diabetes, Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance.
What interventions are being tested in trial NCT04731272?
The interventions under investigation include: Dulaglutide 0.75Mg/0.5Ml Inj Pen (DRUG).
Who is sponsoring clinical trial NCT04731272?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04731272 being conducted?
This trial has 2 study locations across Colorado, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial
COMPLETED · Phase 2
-
Effects of Human Leptin Replacement
COMPLETED · Phase 2
-
A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.